All Studies Meta Analysis Recent:

Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System

Wang et al., medRxiv, doi:10.1101/2020.06.11.20128926

Jun 2020

Post
Facebook

Source PDF All Meta

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020

^*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.

Lower risk for mortality, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19hcq.org

Database analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96, p = 0.82, and HCQ+AZ OR 0.94, p = 0.63

This study is excluded in the after exclusion results of meta analysis: confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.

Important missing comments or errors? Let us know.

risk of death, 5.8% lower, RR 0.94, p = 0.63, treatment 1,866, control 5,726, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Wang et al., 10 Jun 2020, retrospective, database analysis, USA, preprint, 3 authors.

This Paper HCQ All

Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System

PhD An-Li Wang, DrPH Xiaobo Zhong, PhD Yasmin L Hurd

doi:10.1101/2020.06.11.20128926

References

Food, a Clinical Trial Due to Risk of Heart Rhythm Problems

Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents

Goyal, Choi, Pinheiro, Clinical Characteristics of Covid-19 in New York City, N Engl J Med

Grasselli, Zangrillo, Zanella, Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy, JAMA

Guan, Liang, Zhao, Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis, Eur Respir J

Guan, Ni, Hu, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med

Jackson, Busse, Bacharier, Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2, J Allergy Clin Immunol

Richardson, Hirsch, Narasimhan, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA

Rosenberg, Dufort, Udo, Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA

Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis

Society Of Infectious, Centers For Disease, Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020, J Korean Med Sci

Wang, Hu, Hu, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA

Yao, Ye, Zhang, Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis

Zhang, Dong, Cao, Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy

Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0